semaglutide cardiovascular outcomes study news SELECT Trial Cardiovascular Outcomes Associated with Semaglutide

For comparison with other weight loss injectable products: Mounjaro : 20.5% mean weight loss after 48 weeks (estimated from 72 week data) Wegovy (2.4 mg) : 15% mean weight loss after 48 weeks (estimated from 72 week data) Wegovy (7.2 mg) : 18% mean weight loss after 48 weeks (estimated from 72 week data) Therefore, Retatrutide currently shows the most significant weight-loss potential of any GLP-1based drug studied to date

Recent research of the weight loss drug tirzepatide found a significant benefit for OSA

It may also help some people feel full sooner, which can support lower calorie intake and gradual weight loss

Patient education should address both the expected benefits and potential adverse effects of semaglutide, with particular emphasis on gastrointestinal symptoms that may be difficult to distinguish from autoimmune disease manifestations

(2022) demonstrated that LC counteracts insecticide-induced vacuolation and germ cell loss by enhancing testicular antioxidant status and reducing ROS-mediated damage, reinforcing its histological benefits in mild-to-moderate toxicity models